AIGH Capital Management LLC purchased a new stake in shares of Apyx Medical Corporation (NASDAQ:APYX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,128,343 shares of the company's stock, valued at approximately $5,066,000. Apyx Medical accounts for approximately 0.3% of AIGH Capital Management LLC's portfolio, making the stock its 29th largest holding. AIGH Capital Management LLC owned approximately 2.69% of Apyx Medical at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Nantahala Capital Management LLC raised its stake in shares of Apyx Medical by 19.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company's stock valued at $13,909,000 after buying an additional 636,043 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Apyx Medical by 3.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company's stock valued at $3,272,000 after acquiring an additional 53,175 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in shares of Apyx Medical by 0.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company's stock valued at $3,842,000 after acquiring an additional 8,067 shares in the last quarter. Sei Investments Co. increased its stake in Apyx Medical by 298.6% in the first quarter. Sei Investments Co. now owns 598,255 shares of the company's stock valued at $2,208,000 after acquiring an additional 448,174 shares during the period. Finally, Geode Capital Management LLC increased its stake in Apyx Medical by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 358,829 shares of the company's stock valued at $1,257,000 after acquiring an additional 7,551 shares during the period. Institutional investors and hedge funds own 55.33% of the company's stock.
Apyx Medical Price Performance
Shares of APYX opened at $3.03 on Monday. The company has a market capitalization of $127.62 million, a P/E ratio of -15.15 and a beta of 1.39. Apyx Medical Corporation has a one year low of $1.70 and a one year high of $5.08. The business's 50 day simple moving average is $4.15 and its 200-day simple moving average is $3.91. The company has a debt-to-equity ratio of 3.19, a current ratio of 5.68 and a quick ratio of 4.53.
Apyx Medical (NASDAQ:APYX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%.The firm had revenue of $13.88 million during the quarter, compared to analysts' expectations of $13.18 million. As a group, sell-side analysts predict that Apyx Medical Corporation will post -0.25 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on APYX shares. Zacks Research raised Apyx Medical to a "hold" rating in a report on Tuesday, July 14th. Wall Street Zen cut Apyx Medical from a "buy" rating to a "hold" rating in a report on Sunday, April 26th. HC Wainwright initiated coverage on Apyx Medical in a research report on Monday, July 13th. They set a "buy" rating and a $7.00 target price for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Apyx Medical in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $6.60.
Get Our Latest Report on APYX
Apyx Medical Profile
(
Free Report)
Apyx Medical NASDAQ: APYX is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.
Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.
Featured Articles
Want to see what other hedge funds are holding APYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apyx Medical Corporation (NASDAQ:APYX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Apyx Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apyx Medical wasn't on the list.
While Apyx Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
